Bain Capital Private Equity led Kailera Therapeutics’ Series B financing, which will support global Phase 3 tests of KAI-9531, a weekly injectable drug that hits the same targets as Eli Lilly’s blockbuster obesity medication, Zepbound. The capital will also support development of other oral and injectable metabolic medicines in Kailera’s pipeline.
The post Kailera Secures $600M to Advance Dual-Targeting Obesity Drug to Global Phase 3 Tests appeared first on MedCity News.
